Compliance · State rules

Office-use compounding in Connecticut

Split by sterility — non-sterile expressly permitted, sterile patient-specific only

USPeptideRx EditorialLast reviewed: August 30, 2026

Connecticut’s answer changes with the sterility of the preparation — as Illinois’s does — and it has to be stated that way or not at all. For NON-STERILE compounded product it is an express permission on the regulation’s own force: a pharmacy may provide non-patient-specific non-sterile preparations to practitioners to administer to their patients, capped at a thirty-day supply. For STERILE product — which is every injectable preparation this site concerns — a sterile compounding pharmacy may provide only patient-specific product, unless it also registers as a manufacturer with the Department of Consumer Protection. Saying "Connecticut permits office use" is false for every sterile preparation, and saying it prohibits office use erases a real non-sterile permission. Name the limb.

The governing rule

Connecticut’s office-use position is set by RCSA § 20-576-71(c) (non-sterile); Conn. Gen. Stat. § 20-633b(d) (sterile). The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

RCSA § 20-576-71(c) — the non-sterile permission, with its own cap

may provide non-patient specific non-sterile compounded pharmaceutical products to practitioners … to administer to their patients … except that the quantity shall be limited to a thirty day supply

Conn. Gen. Stat. § 20-633b(d)(1) — the sterile limb

may only provide patient-specific sterile pharmaceuticals

Conn. Gen. Stat. § 20-633b(d)(2) — the only way that limb lifts

shall also obtain a certificate of registration from the Department of Consumer Protection pursuant to section 21a-70

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The non-sterile limb is a genuine permission, and it attaches no federal conditionHigh confidence: The regulation grants it directly: non-patient-specific non-sterile compounded product may go to a practitioner to administer to that practitioner’s patients, subject to a thirty-day supply limit. There is no emergency trigger, no commercial-unavailability test and no reference to federal law in the grant.As with every state grant in this file, that it attaches no federal condition makes it effective as Connecticut law and leaves 21 U.S.C. § 353a untouched. The two questions stay independent.
The sterile limb, and what it takes to lift itMedium confidence: A sterile compounding pharmacy may provide only patient-specific sterile pharmaceuticals. Subsection (d)(2) lifts that only where the pharmacy ALSO obtains a certificate of registration from the Department of Consumer Protection under § 21a-70 — which is to say, only by additionally becoming a manufacturer. That is a different credential, not a variation on the pharmacy licence.Marked medium because the sterile outcome rests on reading the 2014 statute as controlling over an older regulation covering similar ground, on later-in-time and more-specific grounds. A single departmental declaratory ruling or a court decision could move it, and the Commission of Pharmacy minutes — the obvious place a regulator would reconcile the two — were not opened.
Three different quantity caps, and they are routinely conflatedHigh confidence: A two-week supply governs sterile preparations supplied to a practitioner under RCSA § 20-576-66(c). A thirty-day supply governs the non-sterile limb under § 20-576-71(c). A separate thirty-day on-site inventory limit, which expressly includes third-party testing time, sits in the statute at § 20-633b(d)(2). Three numbers, three subjects, and quoting one for another is the easiest mistake to make here.
No label legend for compounded preparationsHigh confidence: Searched negative across the whole eighty-one-section regulation set: neither "office stock" nor "not for resale" appears. The only legend Connecticut prescribes is for radiopharmaceuticals.
Connecticut has no 5% clause at allHigh confidence: Its wholesaler carve-outs at § 21a-70(a)(1)(A)–(D) are structural rather than volumetric — they describe kinds of transaction, not a share of sales. A supplier who uses the five-per-cent pitch in other states has nothing to point at in Connecticut.
Entity or person — split by drug class, and the exact mirror of OklahomaHigh confidence: For controlled substances the authority runs to the person: a plain practice company has no registration category to obtain. For legend-drug dispensing it runs to the entity, through the Dispensing Group Practice Registration at § 20-634, $200 biennially. Oklahoma splits the same question the opposite way round, which is why neither state’s answer can be carried across a border.
Read the right revision of the statute, or you will miss a dated dutyHigh confidence: The legislature’s general-statutes pages serve a base revision that omits 2025 legislation entirely; the supplement carries it. Section 20-633b’s history line in the supplement ends with the 2025 act, and that act created a recurring inspection-report duty for nonresident sterile compounding pharmacies. Anyone reading only the base revision reports Connecticut as unchanged since 2023 and misses it.This page was checked against both revisions. It is the clearest example in the file of a citation that resolves, returns the right section, and is still the wrong text.
Last change, and the next dated oneMedium confidence: The 2025 act’s operative sections took effect 1 January 2026, requiring an initial report evidencing an inspection within the preceding six months. Its recurring deadline falls on 30 June of each even-numbered year, so the next is 30 June 2028.

Connecticut at a glance

Connecticut office-use compounding summary, reviewed 2026-08-30
Human office use	Non-sterile permitted; sterile patient-specific only
Sterile preparations	Patient-specific unless the pharmacy also registers as a manufacturer
Quantity cap	Thirty-day non-sterile; two-week sterile; thirty-day on-site inventory
Mandatory label legend	None for compounded preparations
Board reporting	Nonresident sterile compounders file inspection reports biennially
Last change	Inspection-report duty effective January 2026
Governing rule	RCSA § 20-576-71(c) (non-sterile); Conn. Gen. Stat. § 20-633b(d) (sterile)

Receiving 503B office stock in Connecticut

Connecticut licenses these facilities as manufacturers, and not through the pharmacy board: the Commission of Pharmacy approves, and the Department of Consumer Protection’s Drug Control Division issues. Searching Connecticut law for an outsourcing-facility credential returns nothing at all — verified, zero occurrences across the chapter.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Connecticut asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence: A manufacturer certificate of registration from the Department of Consumer Protection under Conn. Gen. Stat. § 21a-70(a)(2)(B). In-state fees are tiered; an out-of-state registration carries no fee and no renewal, which is unusual enough to be worth checking rather than assuming.There is a seam in the exemption at § 21a-70(b), and it cuts against the party most likely to assume it helps. The subsection exempts an out-of-state FDA-registered manufacturer that files its federal registration — but carves a sterile compounding pharmacy back out. So a pure outsourcing facility appears to keep the exemption while a dual-registered pharmacy-and-facility loses it. Whether the department treats a pure facility as inside or outside is unconfirmed; the text supports "inside".
Does your practice need a permit?High confidence: None to hold and administer. A Dispensing Group Practice Registration under § 20-634 is required at $200 biennially where the practice dispenses legend drugs, which is a different act from administering them.
Administer vs dispenseHigh confidence: Dispensing is what pulls a Connecticut practice into a credential it otherwise does not need, and it is also where the entity question flips: the group-practice registration is the one place Connecticut attaches drug authority to a business rather than to a licensed individual.
Scheduled (controlled) stockHigh confidence: Yes, from the Department of Consumer Protection, per practitioner AND per location, and it is triggered by storing, distributing or dispensing at a site rather than by prescribing. The department states that the federal registration is required AFTER the state one, so the sequence runs state first.The fee is stated inconsistently between the statute and the department’s own page, so no single figure is published here.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Whatever Connecticut law allows, federal law applies on top of it and is not satisfied by state permission. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Connecticut compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

The sterile verdict rests on reading a 2014 statute as controlling over an older regulation, on later-in-time and more-specific grounds. It is the weakest link on this page. A departmental declaratory ruling or a Superior Court decision could flip it, and we did not open the Commission of Pharmacy minutes.
Whether the department treats a pure outsourcing facility, not separately licensed as a pharmacy, as inside or outside the § 21a-70(b) exemption is unconfirmed. The statutory text supports "inside", and that is a reading rather than a ruling.
Two fee figures are stated inconsistently across the state’s own sources — the controlled-substance registration and the in-state pharmacy renewal. Neither is published here as a single number.
We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.